Yan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan Wang has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Yu Chen
Department of Cardiology, 920th Hospital of Joint Logistics Support Force of the Chinese People’s Liberation Army, Kunming, China
5 shared publicationsJie Hu
Laboratory of Molecular Cardiology, Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
4 shared publicationsChunxia Ou
Laboratory of Molecular Cardiology, Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
3 shared publicationsJie Yu
Chinese Peoples Liberat Army, Dept Thoracocardiac Surg, 920th Hosp Joint Logist Support Force, Kunming, Yunnan, Peoples R China
3 shared publicationsYue Zhao
Laboratory of Molecular Cardiology, Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
3 shared publicationsChun-Ping Bao
Department of Cardiology, 920th Hospital of Joint Logistics Support Force, Kunming, China
2 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Integrated bioinformatics analysis and mouse validation identify C7 and MFAP4 as candidate genes associated with type 2 diabetes and atherosclerosis
- 6 August 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Open AccessIntegrated bioinformatics analysis and mouse validation identify C7 and MFAP4 as candidate genes associated with type 2 diabetes and atherosclerosis
- 9 January 2026
- Published by ACG Publications in Records of Natural Products
- Vol. 20 (5)
Three new polyacetylenes from Codonopsis pilosula with the activities of lysosomal biogenesis and anti-senescence
Three new polyacetylene glycosides, pilosulynosides A–C (1–3), along with 15 known analogues (4–18), were isolated from the roots of Codonopsis pilosula (Franch.) Nannf. Their structures were determined by 1D and 2D NMR, HRESIMS, and DP4+ probability analysis based on uncalibrated NMR chemical shifts. The promoting effects of all isolated compounds on lysosomal biogenesis were evaluated in HepG2 cells using the LysoTracker Red staining assay. Compounds 1 (pilosulynoside A) and 18 (9-(tetrahydropyran-2-yl)-nona-trans-8-nonene-4,6-diyn-1-ol) showed strong activities in promoting lysosomal biogenesis without cytotoxicity. Mechanistic studies revealed that these effects were independent of the classical TFEB/TFE3 pathways. Furthermore, compounds 1 and 18 displayed anti-senescence activity in a senescence model of rat cardiac microvascular endothelial cells (CMECs). These findings indicate that polyacetylenes from C. pilosula can promote lysosomal biogenesis via a TFEB/TFE3-independent mechanism and exert anti-senescence effects, offering new lead compounds for therapeutic interventions in senescence and lysosome-related diseases.
- 9 January 2026
- Published by ACG Publications in Records of Natural Products
- Vol. 20 (5)
Three new polyacetylenes from Codonopsis pilosula with the activities of lysosomal biogenesis and anti-senescence
Three new polyacetylene glycosides, pilosulynosides A–C (1–3), along with 15 known analogues (4–18), were isolated from the roots of Codonopsis pilosula (Franch.) Nannf. Their structures were determined by 1D and 2D NMR, HRESIMS, and DP4+ probability analysis based on uncalibrated NMR chemical shifts. The promoting effects of all isolated compounds on lysosomal biogenesis were evaluated in HepG2 cells using the LysoTracker Red staining assay. Compounds 1 (pilosulynoside A) and 18 (9-(tetrahydropyran-2-yl)-nona-trans-8-nonene-4,6-diyn-1-ol) showed strong activities in promoting lysosomal biogenesis without cytotoxicity. Mechanistic studies revealed that these effects were independent of the classical TFEB/TFE3 pathways. Furthermore, compounds 1 and 18 displayed anti-senescence activity in a senescence model of rat cardiac microvascular endothelial cells (CMECs). These findings indicate that polyacetylenes from C. pilosula can promote lysosomal biogenesis via a TFEB/TFE3-independent mechanism and exert anti-senescence effects, offering new lead compounds for therapeutic interventions in senescence and lysosome-related diseases.
- Open Access
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1621491
Differential expression of platelet CD147 in moderate altitude conditions: implications for coronary plaque stability assessment
Background: As a major contributor to global death rates, coronary heart disease (CHD) remains critical. This investigation examines CD147's utility for assessing plaque characteristics among CHD patients, with a focus on moderate altitude populations. Methods: Initially, high-throughput sequencing was performed on platelet samples obtained from three individuals with stable angina (SA) and three with unstable angina (UA), serving as the discovery cohort for subsequent bioinformatics analysis. Based on the insights gained from this initial phase, the investigation was extended to a larger cohort comprising 90 SA patients and 90 individuals diagnosed with acute coronary syndrome (ACS). Platelets isolated from these patients underwent flow cytometry analysis for CD147 expression. Furthermore, a logistic regression analysis incorporating traditional CHD risk factors was conducted to determine the odds ratio (OR) for CD147 expression in differentiating between stable and unstable plaques. Results: High-throughput sequencing revealed distinct CD147 levels between SA and UA groups (log₂FC = 2.3). The logistic regression analysis demonstrated that heightened platelet CD147 correlated with plaque instability (OR = 9.21, 95% CI: 2.33–36.42, P = 0.002), persisting beyond conventional risk adjustment. Conclusion: This study identifies platelet CD147 as a promising predictor for differentiating plaque stability in CHD under moderate altitude conditions. Our findings suggest that CD147 not only contributes to platelet activation and thrombus formation but may also directly influence plaque stability. The impact of chronic hypoxia and other environmental stressors in moderate altitude regions on CD147 expression provides new insights for risk stratification and targeted therapeutic strategies in altitude-specific populations.
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1621491
Open AccessDifferential expression of platelet CD147 in moderate altitude conditions: implications for coronary plaque stability assessment
Background: As a major contributor to global death rates, coronary heart disease (CHD) remains critical. This investigation examines CD147's utility for assessing plaque characteristics among CHD patients, with a focus on moderate altitude populations. Methods: Initially, high-throughput sequencing was performed on platelet samples obtained from three individuals with stable angina (SA) and three with unstable angina (UA), serving as the discovery cohort for subsequent bioinformatics analysis. Based on the insights gained from this initial phase, the investigation was extended to a larger cohort comprising 90 SA patients and 90 individuals diagnosed with acute coronary syndrome (ACS). Platelets isolated from these patients underwent flow cytometry analysis for CD147 expression. Furthermore, a logistic regression analysis incorporating traditional CHD risk factors was conducted to determine the odds ratio (OR) for CD147 expression in differentiating between stable and unstable plaques. Results: High-throughput sequencing revealed distinct CD147 levels between SA and UA groups (log₂FC = 2.3). The logistic regression analysis demonstrated that heightened platelet CD147 correlated with plaque instability (OR = 9.21, 95% CI: 2.33–36.42, P = 0.002), persisting beyond conventional risk adjustment. Conclusion: This study identifies platelet CD147 as a promising predictor for differentiating plaque stability in CHD under moderate altitude conditions. Our findings suggest that CD147 not only contributes to platelet activation and thrombus formation but may also directly influence plaque stability. The impact of chronic hypoxia and other environmental stressors in moderate altitude regions on CD147 expression provides new insights for risk stratification and targeted therapeutic strategies in altitude-specific populations.
- Open Access
- 26 September 2024
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 40, 101833
CEACAM1 increased the lymphangiogenesis through miR-423-5p and NF- kB in Non-Small Cell Lung Cancer
- 26 September 2024
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 40, 101833
Open AccessCEACAM1 increased the lymphangiogenesis through miR-423-5p and NF- kB in Non-Small Cell Lung Cancer
- Open Access
- 13 September 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1425817
Integrating genomic profiling to clinical data: assessing the impact of CD147 expression on plaque stability
Background: Acute Coronary Syndrome (ACS) continues to be a leading cause of death and illness worldwide. Differentiating stable from unstable coronary plaques is essential for enhancing patient outcomes. This research investigates the role of CD147 as a biomarker for plaque stability among coronary artery disease patients.Methods: The study began with high-throughput sequencing of blood samples from six patients, divided equally between those with Stable Angina (SA) and Unstable Angina (UA), followed by bioinformatics analysis. Expanding upon these findings, the study included 31 SA patients and 30 patients with ACS, using flow cytometry to examine CD147 expression on platelets and monocytes. Additionally, logistic regression was utilized to integrate traditional risk factors and evaluate the predictive value of CD147 expression for plaque stability.Results: Initial sequencing displayed a notable difference in CD147 expression between SA and UA groups, with a significant increase in UA patients. Further analysis confirmed that elevated platelet CD147 expression was strongly associated with unstable plaques (OR = 277.81, P < .001), after adjusting for conventional risk factors, whereas monocyte CD147 levels did not show a significant difference.Conclusion: Elevated CD147 expression on platelets is a crucial biomarker for identifying unstable coronary artery plaques, offering insights into patient risk stratification and the development of targeted treatment strategies. This underscores the pivotal role of molecular research in understanding and managing coronary artery disease, paving the way for improved clinical outcomes.
- 13 September 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1425817
Open AccessIntegrating genomic profiling to clinical data: assessing the impact of CD147 expression on plaque stability
Background: Acute Coronary Syndrome (ACS) continues to be a leading cause of death and illness worldwide. Differentiating stable from unstable coronary plaques is essential for enhancing patient outcomes. This research investigates the role of CD147 as a biomarker for plaque stability among coronary artery disease patients.Methods: The study began with high-throughput sequencing of blood samples from six patients, divided equally between those with Stable Angina (SA) and Unstable Angina (UA), followed by bioinformatics analysis. Expanding upon these findings, the study included 31 SA patients and 30 patients with ACS, using flow cytometry to examine CD147 expression on platelets and monocytes. Additionally, logistic regression was utilized to integrate traditional risk factors and evaluate the predictive value of CD147 expression for plaque stability.Results: Initial sequencing displayed a notable difference in CD147 expression between SA and UA groups, with a significant increase in UA patients. Further analysis confirmed that elevated platelet CD147 expression was strongly associated with unstable plaques (OR = 277.81, P < .001), after adjusting for conventional risk factors, whereas monocyte CD147 levels did not show a significant difference.Conclusion: Elevated CD147 expression on platelets is a crucial biomarker for identifying unstable coronary artery plaques, offering insights into patient risk stratification and the development of targeted treatment strategies. This underscores the pivotal role of molecular research in understanding and managing coronary artery disease, paving the way for improved clinical outcomes.
- Open Access
- 8 May 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-13
miR-449a disturbs atherosclerotic plaque stability in streptozotocin and high-fat diet-induced diabetic mice by targeting CEACAM1
Background: Emerging evidence indicates carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is involved in the development of atherosclerosis (AS). However, the roles and functions of CEACAM1 in AS remain unknown. Therefore, this study aims to investigate the roles and molecular functions of CEACAM1 in AS. Methods: We constructed a diabetes mellitus (DM) + high-fat diet (HFD) mouse model based on the streptozotocin (STZ)-induced apolipoprotein E-knockdown (ApopE−/−) mouse to investigate the roles and regulatory mechanism of miR-449a/CEACAM1 axis. The mRNA expression and protein levels in this study were examined using quantity PCR, western blot, immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry (IHC), respectively. And the lipid deposition and collagen content were detected using Oil Red O and Sirius Red staining. Cell apoptosis, migration, invasion, and tuber formation were detected by Annexin-V FITC/PI, wound healing, transwell, and tuber formation assays, respectively. The relationship between miR-449a and CEACAM1 was determined by a dual-luciferase reporter gene assay. Results: miR-449a and MMP-9 were upregulated, and CEACAM1 was downregulated in the DM + HFD MOUSE model. Upregulation of CEACAM1 promoted atherosclerotic plaque stability and inhibited inflammation in the DM + HFD mouse model. And miR-449a directly targeted CEACAM1. Besides, miR-449a interacted with CEACAM1 to regulate atherosclerotic plaque stability and inflammation in DM-associated AS mice. In vitro, the rescue experiments showed miR-449a interacted with CEACAM1 to affect apoptosis, migration, invasion, and tuber formation ability in high glucose (HG)-induced HUVECs. Conclusion: These results demonstrated that miR-449a promoted plaque instability and inflammation in DM and HFD-induced mice by targeting CEACAM1.
- 8 May 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-13
Open AccessmiR-449a disturbs atherosclerotic plaque stability in streptozotocin and high-fat diet-induced diabetic mice by targeting CEACAM1
Background: Emerging evidence indicates carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is involved in the development of atherosclerosis (AS). However, the roles and functions of CEACAM1 in AS remain unknown. Therefore, this study aims to investigate the roles and molecular functions of CEACAM1 in AS. Methods: We constructed a diabetes mellitus (DM) + high-fat diet (HFD) mouse model based on the streptozotocin (STZ)-induced apolipoprotein E-knockdown (ApopE−/−) mouse to investigate the roles and regulatory mechanism of miR-449a/CEACAM1 axis. The mRNA expression and protein levels in this study were examined using quantity PCR, western blot, immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry (IHC), respectively. And the lipid deposition and collagen content were detected using Oil Red O and Sirius Red staining. Cell apoptosis, migration, invasion, and tuber formation were detected by Annexin-V FITC/PI, wound healing, transwell, and tuber formation assays, respectively. The relationship between miR-449a and CEACAM1 was determined by a dual-luciferase reporter gene assay. Results: miR-449a and MMP-9 were upregulated, and CEACAM1 was downregulated in the DM + HFD MOUSE model. Upregulation of CEACAM1 promoted atherosclerotic plaque stability and inhibited inflammation in the DM + HFD mouse model. And miR-449a directly targeted CEACAM1. Besides, miR-449a interacted with CEACAM1 to regulate atherosclerotic plaque stability and inflammation in DM-associated AS mice. In vitro, the rescue experiments showed miR-449a interacted with CEACAM1 to affect apoptosis, migration, invasion, and tuber formation ability in high glucose (HG)-induced HUVECs. Conclusion: These results demonstrated that miR-449a promoted plaque instability and inflammation in DM and HFD-induced mice by targeting CEACAM1.
- 5 January 2024
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 24 (2) , 133-145
miRNA-146a-5p Inhibits Hypoxia-Induced Myocardial Fibrosis Through EndMT
Cardiac Vascular disease particularly myocardial infarction (MI) is a threat to health worldwide. microRNAs (miRNAs) have been shown to regulate myocardial fibrosis. Therefore, it is potential to investigate the mechanism of miRNA and fibrosis following myocardial infarction. Hypoxia human cardiac microvascular endothelial cells (HCMECs) were selected for the vitro experimental model. The miR-146a-5p expression was tested via RT-qPCR. The level of endothelial-to-mesenchymal transition (EndMT) and fibrosis markers were detected by Western blotting and immunofluorescence. Then, the inflammation, cell viability and apoptosis were investigated. The target was predicted by an online database and verified by a dual-luciferase activity assay. An MI mouse model was created to validate that miR-146a-5p regulates cardiac fibrosis in vivo. MI mouse was transfected with miR-146a-5p lentivirus. Subsequently, its effect on cardiac fibrosis of infarcted hearts was assessed by In situ hybridization (ISH), Immunohistochemistry (IHC), Triphenylterazolium chloride (TTC) staining and Masson staining. Herein, we confirmed that miR-146a-5p was down-regulated in hypoxia HCMECs. Overexpression of miR-146a-5p inhibited hypoxia-induced cardiac fibrosis following myocardial infarction by inhibiting EndMT in HCMECs. Thioredoxin-interacting protein (TXNIP) was a target that was negatively regulated by miR-146a-5p. Up-regulation of miR-146a-5p inhibited cardiac fibrosis via regulating EndMT by targeting TXNIP, and it also regulated EndMT to inhibit cardiac fibrosis in vivo.
- 5 January 2024
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 24 (2) , 133-145
miRNA-146a-5p Inhibits Hypoxia-Induced Myocardial Fibrosis Through EndMT
Cardiac Vascular disease particularly myocardial infarction (MI) is a threat to health worldwide. microRNAs (miRNAs) have been shown to regulate myocardial fibrosis. Therefore, it is potential to investigate the mechanism of miRNA and fibrosis following myocardial infarction. Hypoxia human cardiac microvascular endothelial cells (HCMECs) were selected for the vitro experimental model. The miR-146a-5p expression was tested via RT-qPCR. The level of endothelial-to-mesenchymal transition (EndMT) and fibrosis markers were detected by Western blotting and immunofluorescence. Then, the inflammation, cell viability and apoptosis were investigated. The target was predicted by an online database and verified by a dual-luciferase activity assay. An MI mouse model was created to validate that miR-146a-5p regulates cardiac fibrosis in vivo. MI mouse was transfected with miR-146a-5p lentivirus. Subsequently, its effect on cardiac fibrosis of infarcted hearts was assessed by In situ hybridization (ISH), Immunohistochemistry (IHC), Triphenylterazolium chloride (TTC) staining and Masson staining. Herein, we confirmed that miR-146a-5p was down-regulated in hypoxia HCMECs. Overexpression of miR-146a-5p inhibited hypoxia-induced cardiac fibrosis following myocardial infarction by inhibiting EndMT in HCMECs. Thioredoxin-interacting protein (TXNIP) was a target that was negatively regulated by miR-146a-5p. Up-regulation of miR-146a-5p inhibited cardiac fibrosis via regulating EndMT by targeting TXNIP, and it also regulated EndMT to inhibit cardiac fibrosis in vivo.
- Open Access
- 11 July 2022
- Published by Wiley in Disease Markers
- Vol. 2022, 1-22
miR-26a-5p Suppresses Wnt/β-Catenin Signaling Pathway by Inhibiting DNMT3A-Mediated SFRP1 Methylation and Inhibits Cancer Stem Cell-Like Properties of NSCLC
Background. Lung cancer is a malignant cancer which results in the most cancer incidence and mortality worldwide. There is increasing evidence that the pattern of DNA methylation affects tumorigenesis and progression. However, the molecules and mechanisms regulating DNA methylation remain unclear. Methods. The expression of miR-26a-5p in NSCLC cell lines was detected by qPCR and verified in NSCLC tissues from TCGA using Limma R package. CCK-8 assay, plate clone formation assay, flow cytometry, and sphere formation assay were used to detect the cell proliferation, colony formation, cell cycle, and cancer stem cell- (CSC-) like property in NSCLC cell lines. The immunoblotting was used to detect the protein levels of DNMT3A, SFRP1, and Ki67. Global DNA methylation levels and DNA methylation levels of SFRP1 promoter were examined using ELISA and MSP-PCR assay, respectively. The distribution of β-catenin was examined using immunofluorescence (IF). Besides, xenograft mouse model was used to investigate the antitumor effects of miR-26a-5p in vivo. The pathology and protein levels were, respectively, detected by hematoxylin and eosin (HE) and immunocytochemistry (IHC). Results. The expression of miR-26a-5p was downregulated in the tumor tissues comparted to adjacent normal tissues as well as NSCLC cell lines compared to normal lung epithelial cell (BEAS2B). The overexpression of miR-26a-5p inhibited cell proliferation, colony formation, CSC-like property, and arrested cell cycle at G1 phase. DNMT3A was a target of miR-26a-5p and upregulated DNA methylation on SFRP1 promoter. Mechanistically, miR-26a-5p repressed cell proliferation, colony formation, CSC-like property, and arrested cell cycle at G1 phase by binding DNMT3A to reduce DNA methylation levels of SFRP1 then upregulated SFRP1 expression. Moreover, miR-26a-5p exerted antitumor effects in vivo. Conclusion. Our results revealed that miR-26a-5p acted as a tumor suppressor through targeting DNMT3A to upregulate SFRP1 via reducing DNMT3A-dependent DNA methylation.
- 11 July 2022
- Published by Wiley in Disease Markers
- Vol. 2022, 1-22
Open AccessmiR-26a-5p Suppresses Wnt/β-Catenin Signaling Pathway by Inhibiting DNMT3A-Mediated SFRP1 Methylation and Inhibits Cancer Stem Cell-Like Properties of NSCLC
Background. Lung cancer is a malignant cancer which results in the most cancer incidence and mortality worldwide. There is increasing evidence that the pattern of DNA methylation affects tumorigenesis and progression. However, the molecules and mechanisms regulating DNA methylation remain unclear. Methods. The expression of miR-26a-5p in NSCLC cell lines was detected by qPCR and verified in NSCLC tissues from TCGA using Limma R package. CCK-8 assay, plate clone formation assay, flow cytometry, and sphere formation assay were used to detect the cell proliferation, colony formation, cell cycle, and cancer stem cell- (CSC-) like property in NSCLC cell lines. The immunoblotting was used to detect the protein levels of DNMT3A, SFRP1, and Ki67. Global DNA methylation levels and DNA methylation levels of SFRP1 promoter were examined using ELISA and MSP-PCR assay, respectively. The distribution of β-catenin was examined using immunofluorescence (IF). Besides, xenograft mouse model was used to investigate the antitumor effects of miR-26a-5p in vivo. The pathology and protein levels were, respectively, detected by hematoxylin and eosin (HE) and immunocytochemistry (IHC). Results. The expression of miR-26a-5p was downregulated in the tumor tissues comparted to adjacent normal tissues as well as NSCLC cell lines compared to normal lung epithelial cell (BEAS2B). The overexpression of miR-26a-5p inhibited cell proliferation, colony formation, CSC-like property, and arrested cell cycle at G1 phase. DNMT3A was a target of miR-26a-5p and upregulated DNA methylation on SFRP1 promoter. Mechanistically, miR-26a-5p repressed cell proliferation, colony formation, CSC-like property, and arrested cell cycle at G1 phase by binding DNMT3A to reduce DNA methylation levels of SFRP1 then upregulated SFRP1 expression. Moreover, miR-26a-5p exerted antitumor effects in vivo. Conclusion. Our results revealed that miR-26a-5p acted as a tumor suppressor through targeting DNMT3A to upregulate SFRP1 via reducing DNMT3A-dependent DNA methylation.
- Open Access
- 5 May 2022
- Published by Springer Nature in Research Square
MiR-449a disturbs atherosclerotic plaque stability in streptozotocin and high-fat diet-induced diabetic mice by targeting CEACAM1
Background Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) acts as an important role in atherosclerosis (AS), but the function of CEACAM1 in diabetes mellitus (DM) associated AS remains unclear. Thus, the purposes of this study are to explore the function and potential mechanism of CEACAM1 in DM-associated AS. Methods The streptozotocin (STZ)-induced apolipoprotein E-knockdown (ApopE−/−) mice were used to explore the function and regulatory mechanism of miR-449a/CEACAM1 axis in DM-associated AS. Quantity PCR, western blot, immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry (IHC) were utilized to detect mRNA expression, and protein levels, respectively. Oil Red O and Sirius Red staining were used to detect the lipid deposition and collagen content. Cell apoptosis, migration, invasion, and tuber formation were detected by Annexin-V FITC/PI, wound healing, transwell, and tuber formation assays, respectively. The relationship between miR-449a and CEACAM1 was determined by a dual-luciferase reporter gene assay. Results We found miR-449a and MMP-9 upregulated whereas CEACAM1 downregulated in DM-associated AS model. Function experiments indicated that upregulation of CEACAM1 promoted atherosclerotic plaque stability and inhibited inflammation in DM-associated AS model. Dual-luciferase reporter gene assay demonstrated that miR-449a targeted CEACAM1. And the rescue experiments revealed that miR-449a interacted with CEACAM1 to regulate atherosclerotic plaque stability and inflammation in DM-associated AS mice. In vitro, the rescue experiments showed miR-449a interacted with CEACAM1 to affect apoptosis, migration, invasion, and tuber formation ability in high glucose (HG)-induced HUVECs. Conclusion Our finding suggested that miR-449a promoted plaque instability and inflammation in DM and HFD-induced mice by targeting CEACAM1.
- 5 May 2022
- Published by Springer Nature in Research Square
Open AccessMiR-449a disturbs atherosclerotic plaque stability in streptozotocin and high-fat diet-induced diabetic mice by targeting CEACAM1
Background Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) acts as an important role in atherosclerosis (AS), but the function of CEACAM1 in diabetes mellitus (DM) associated AS remains unclear. Thus, the purposes of this study are to explore the function and potential mechanism of CEACAM1 in DM-associated AS. Methods The streptozotocin (STZ)-induced apolipoprotein E-knockdown (ApopE−/−) mice were used to explore the function and regulatory mechanism of miR-449a/CEACAM1 axis in DM-associated AS. Quantity PCR, western blot, immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry (IHC) were utilized to detect mRNA expression, and protein levels, respectively. Oil Red O and Sirius Red staining were used to detect the lipid deposition and collagen content. Cell apoptosis, migration, invasion, and tuber formation were detected by Annexin-V FITC/PI, wound healing, transwell, and tuber formation assays, respectively. The relationship between miR-449a and CEACAM1 was determined by a dual-luciferase reporter gene assay. Results We found miR-449a and MMP-9 upregulated whereas CEACAM1 downregulated in DM-associated AS model. Function experiments indicated that upregulation of CEACAM1 promoted atherosclerotic plaque stability and inhibited inflammation in DM-associated AS model. Dual-luciferase reporter gene assay demonstrated that miR-449a targeted CEACAM1. And the rescue experiments revealed that miR-449a interacted with CEACAM1 to regulate atherosclerotic plaque stability and inflammation in DM-associated AS mice. In vitro, the rescue experiments showed miR-449a interacted with CEACAM1 to affect apoptosis, migration, invasion, and tuber formation ability in high glucose (HG)-induced HUVECs. Conclusion Our finding suggested that miR-449a promoted plaque instability and inflammation in DM and HFD-induced mice by targeting CEACAM1.